Same parts, same bond
A peptide and a protein are built from the same units — amino acids — joined by the same link, the peptide bond. Neither the atoms nor the bond change as a chain grows. What changes is length, and with length, the tendency to fold into a stable three-dimensional shape.
So the question "peptide or protein?" is not answered by chemistry. It is answered by whoever is drawing the line, and different fields draw it in different places. This page is about where those lines fall. What a peptide is in the first place is set out in the plain definition of a peptide, and how chains are numbered and how long this library's compounds actually are is in the peptide chain entry.
The scientific convention: roughly 50, loosely held
In textbooks and papers the boundary moves between about 40 and 100 residues, most often quoted near 50. Below it, "peptide" or "polypeptide"; above it, "protein". Two practical habits sit behind the number:
- Folding. Longer chains tend to fold into a stable structure that does the work. A short peptide usually has no fixed shape of its own until it binds something.
- Making it. Short chains are made by chemical synthesis on a resin, one amino acid at a time. Long ones have historically been made by living cells.
Neither habit gives a sharp edge, which is why the same molecule can be a "large peptide" in one paper and a "small protein" in the next.
The one hard number: US drug law says over 40
Regulation needs a line it can apply, and US law has one. 21 CFR 600.3(h)(6), read from the eCFR on 2026-09-21:
"A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size."
Two further clauses do most of the work.
- Chains that belong together are added up. Where two or more chains are associated "in a manner that occurs in nature", the size is the total of their amino acids, "not limited to the number of amino acids in a contiguous sequence."
- How it is made does not matter. The statutory definition of a biological product once excluded "any chemically synthesized polypeptide". The Further Consolidated Appropriations Act, 2020, enacted 20 December 2019, removed that exception. A protein built on a synthesiser is a biologic, the same as one grown in cells.
Insulin: 21 + 30 = 51, and a change of pathway
Insulin is the case the counting clause decides. It has two chains, of 21 and 30 amino acids, held together by disulfide bonds. Neither chain alone passes 40. Counted together, as the rule requires, they make 51 — a protein.
For decades insulin had been approved as a drug. The Biologics Price Competition and Innovation Act of 2010 gave such products a ten-year transition, and on 23 March 2020 their drug approvals were deemed to be biologics licences. FDA's own list of the products affected names insulin and insulin analogues, human growth hormone, pancreatic enzymes and reproductive hormones.
The label records still carry the seam. Humulin R is listed in Drugs@FDA as BLA018780 — a biologics licence carrying its old drug-application number.
Semaglutide: 31, and still a drug
The GLP-1 drugs in this library fall on the other side. Semaglutide is a 31-amino-acid chain with a fatty side chain attached, under the 40 line, and its US products remain new drug applications in Drugs@FDA (checked 2026-09-21). The same holds for most compounds this library covers: BPC-157 is 15 amino acids, TB-500 a 7-residue fragment.
The larger molecules in this library are on the protein side by any definition. Follistatin runs to 288 or 315 amino acids, and the myostatin drugs such as the antibody bimagrumab are full-size antibodies. A reader meeting them in a list of "peptides" is meeting a naming habit of the market, not a chemical category.
Why the line matters
| If a molecule is… | In US law it is… | What follows |
|---|---|---|
| 40 amino acids or fewer | a drug (if approved) | new drug application; copies reach market as generics |
| over 40, counting associated chains | a biologic | biologics licence; copies reach market as biosimilars |
For a reader, the practical point is smaller and more useful: when two sources disagree about whether something is a peptide or a protein, they are usually both right, each using a different line. Only in US drug regulation is the answer a number, and that number is 40.
Last checked
2026-09-21. The protein definition read from 21 CFR 600.3 through the eCFR API; the transition date, the product list and the 2019 amendment from FDA's page on the BPCI Act "deemed to be a license" provision; application types for Humulin R and semaglutide from Drugs@FDA through the openFDA API.